# The Whole-course Management of Pegaspargase in ENKTL

> **NCT05426824** · NA · UNKNOWN · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 72 (estimated)

## Conditions studied

- Extranodal NK/T Cell Lymphoma

## Interventions

- **DRUG:** Pegaspargase（P-GOD）
- **DRUG:** Pegaspargase（PEMD）

## Key facts

- **NCT ID:** NCT05426824
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-07-01
- **Primary completion:** 2024-07-15
- **Final completion:** 2025-07-15
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2022-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05426824

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05426824, "The Whole-course Management of Pegaspargase in ENKTL". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05426824. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*